ChromaDex (CDXC) Reports In-Line Q4 EPS, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
March 10, 2020 4:01 PM EDTFourth Quarter 2019 Highlights vs. Fourth Quarter 2018
Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.Tru Niagen® net sales of $10.2 million, a 57% increase year-over-year.Net loss per share of ($0.15) as reported, or non-GAAP net loss per share of ($0.11) excluding a $0.04 per share charge related to the non-cash write-off of Elysium receivable as bad debt expense.Expanded distribution rights with Matakana in Australia and secured partnership with a leading health and beauty retailer to launch in over 200 U.K. stores in... More